Ultragenyx Pharmaceutical Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of RARE for the last quarter is 127.39 M USD, and it's 29.92% higher compared to the previous quarter. The net income of Q4 23 is -123.19 M USD.